Stock Market News

Cassava Sciences ends Alzheimer's treatment development after unsuccessful trials

Mar 25, 2025 - 14:02
 0
Cassava Sciences ends Alzheimer's treatment development after unsuccessful trials
Read More

Tags:

Previous Article

FactSet price target lowered to $466 from $498 at BMO Capital

Next Article

Cognizant boosts stock buyback program by $2 billion

Related Posts

Salesforce forecasts annual revenue below estimates

Salesforce forecasts annual revenue below estimates

Feb 26, 2025  0

Elon Musk holds Pentagon meeting, wants leakers prosecuted

Elon Musk holds Pentagon meeting, wants leakers prosecuted

Mar 21, 2025  0

French car lobby PFA: there can only be losers in a trade war

French car lobby PFA: there can only be losers in a tra...

Mar 27, 2025  0